XERIS Pharmaceuticals Inc (XERS):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:XERIS Pharmaceuticals Inc (XERS) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7871
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
XERIS Pharmaceuticals Inc (XERIS) is a specialty pharmaceutical company that develops and commercializes injectable and infusible drug formulations. The company’s proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of ultra concentrated formulations of proteins, peptides, antibodies and small molecules using syringes, multi-dose pens, auto-injectors and pumps. Its products are used for various therapeutic areas, including severe hypoglycemia, post-bariatric hypoglycemia, congenital hyperinsulinism, hypoglycemia-associated autonomic failure, exercise-induced hypoglycemia, acute repetitive seizures and type 1/type 2 blood sugar control. The company caters caregivers, health practitioners and patients. XERIS is headquartered in Chicago, Illinois, the US.

XERIS Pharmaceuticals Inc (XERS) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
XERIS Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
XERIS Pharmaceuticals Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
XERIS Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
XERIS Pharmaceuticals Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
XERIS Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
XERIS Pharmaceuticals Inc, Medical Equipment, Deal Details 10
Venture Financing 10
XERIS Pharma Raises USD10 Million in Series C Equity Financing 10
Xeris Pharma Raises Additional USD30 Million in Series C Financing 11
XERIS Pharma Raises USD0.2 Million in Venture Financing 13
Partnerships 14
Xeris Pharma Enters into Joint Development Agreement Scandinavian Health 14
Equity Offering 15
Xeris Pharma Raises USD98.3 Million in IPO of Shares 15
Xeris Pharma Raises USD13 Million in Private Placement of Preferred Shares 16
XERIS Pharmaceuticals Inc – Key Competitors 17
XERIS Pharmaceuticals Inc – Key Employees 18
XERIS Pharmaceuticals Inc – Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Financial Announcements 20
Aug 13, 2018: Xeris Pharmaceuticals Announces Second Quarter 2018 Financial Results and Business Highlights 20
Corporate Communications 21
Sep 07, 2017: Xeris Pharmaceuticals Appoints John P. Schmid to Board of Directors 21
Jan 09, 2017: Xeris Pharmaceuticals Announces Appointment of Paul R. Edick as President and CEO 22
Product News 23
Jun 05, 2017: Xeris Pharmaceuticals’ Ready-to-Use Liquid Glucagon Clinical Data to Be Presented at American Diabetes Association 77th Scientific Sessions 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
XERIS Pharmaceuticals Inc, Medical Equipment, Key Facts, 2017 2
XERIS Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
XERIS Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
XERIS Pharmaceuticals Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
XERIS Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
XERIS Pharmaceuticals Inc, Deals By Market, 2012 to YTD 2018 8
XERIS Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
XERIS Pharma Raises USD10 Million in Series C Equity Financing 10
Xeris Pharma Raises Additional USD30 Million in Series C Financing 11
XERIS Pharma Raises USD0.2 Million in Venture Financing 13
Xeris Pharma Enters into Joint Development Agreement Scandinavian Health 14
Xeris Pharma Raises USD98.3 Million in IPO of Shares 15
Xeris Pharma Raises USD13 Million in Private Placement of Preferred Shares 16
XERIS Pharmaceuticals Inc, Key Competitors 17
XERIS Pharmaceuticals Inc, Key Employees 18

List of Figures
XERIS Pharmaceuticals Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
XERIS Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
XERIS Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
XERIS Pharmaceuticals Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
XERIS Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
XERIS Pharmaceuticals Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
XERIS Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
XERIS Pharmaceuticals Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★海外企業調査レポート[XERIS Pharmaceuticals Inc (XERS):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Orica Ltd:企業の戦略・SWOT・財務情報
    Orica Ltd - Strategy, SWOT and Corporate Finance Report Summary Orica Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Covalon Technologies Ltd (COV):企業の財務・戦略的SWOT分析
    Summary Covalon Technologies Ltd (Covalon) is a researcher, developer and commercializer of medical products and healthcare technologies. The company offers advanced wound care, infection prevention and perioperative care products. Its wound care products include collagen matrix dressing, collagen m …
  • Dentsply Sirona Inc (XRAY):企業の財務・戦略的SWOT分析
    Dentsply Sirona Inc (XRAY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Yamada Denki Co Ltd:企業の戦略・SWOT・財務情報
    Yamada Denki Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Yamada Denki Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Julius Baer:企業のM&A・事業提携・投資動向
    Julius Baer - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Julius Baer Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • TopiVert Ltd-製薬・医療分野:企業M&A・提携分析
    Summary TopiVert Ltd (TopiVert) is a drug development company that offers disease control solutions in inflammatory diseases of the gastrointestinal tract and the eye. The company develops and offers narrow spectrum kinase inhibitors (NSKI) for the treatment of chronic inflammatory diseases of gastr …
  • TransDigm Group Incorporated:企業の戦略・SWOT・財務情報
    TransDigm Group Incorporated - Strategy, SWOT and Corporate Finance Report Summary TransDigm Group Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Ferring International Center SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Ferring International Center SA (Ferring) researches, develops and markets pharmaceutical products. The company offers pharmaceutical products in the fields of reproductive health, gastroenterology, endocrinology, urology and orthopedics. Some of the marketed products include Rekovelle (foll …
  • Pentax Europe GmbH:医療機器:M&Aディール及び事業提携情報
    Summary Pentax Europe GmbH (Pentax Medical), a subsidiary of Hoya Corp, is a medical device company that offers clinical endo-imaging solutions. The company provides products in the therapeutic areas of gastroenterology, endoscopic ultrasound, ENT and speech, pulmonology and urology, among others. I …
  • AB-Biotics SA (ABB)-製薬・医療分野:企業M&A・提携分析
    Summary AB-Biotics SA (AB-Biotics) is a provider of probiotics, specialty dietary supplements, pipeline products and other functional ingredients. The company’s products comprise probiotic products, iron-containing ingredients, lactobacillus plantarum, lactobacillus brevis, natural solutions, gastro …
  • Pioneer Natural Resources Co (PXD):企業の財務・戦略的SWOT分析
    Pioneer Natural Resources Co (PXD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Hospira Inc:医療機器:M&Aディール及び事業提携情報
    Summary Hospira Inc (Hospira), a subsidiary of Pfizer Inc, is a medical device company that offers injectable drugs and infusion technologies. The company offers products such as generic acute-care and oncology injectables, biosimilars, infusion systems, IV sets, IV safety devices, biosimilars, diff …
  • Ten Network Holdings Ltd:企業の戦略的SWOT分析
    Ten Network Holdings Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • PT Bank CIMB Niaga Tbk (BNGA)
    PT Bank CIMB Niaga Tbk (BNGA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Nokia Corp (NOKIA):企業の財務・戦略的SWOT分析
    Nokia Corp (NOKIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • UnitedHealth Group Incorporated:企業の戦略・SWOT・財務分析
    UnitedHealth Group Incorporated - Strategy, SWOT and Corporate Finance Report Summary UnitedHealth Group Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Cytokinetics Inc (CYTK):企業の財務・戦略的SWOT分析
    Cytokinetics Inc (CYTK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • FBD Holdings Plc (EG7):企業の財務・戦略的SWOT分析
    FBD Holdings Plc (EG7) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Bumi Armada Berhad (ARMADA):石油・ガス:M&Aディール及び事業提携情報
    Summary Bumi Armada Bhd (Bumi Armada) is an integrated offshore solutions provider. The company owns and operates Floating Production Storage & Offloading (FPSO), Offshore Support Vessels (OSV), pipelaying barges, and subsea vessels. Its FPSO portfolio includes Armada TGT 1, Armada Sterling, Armada …
  • Amarantus Bioscience Holdings Inc:企業のM&A・事業提携・投資動向
    Amarantus Bioscience Holdings Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Amarantus Bioscience Holdings Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mer …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆